Maximizing Investigators' Research Award (MIRA) (R35 - Clinical Trial Optional)

Open Posted

Opportunity number
PAR-26-121
Agency
Applications due
Award size
Not on record

Opportunity facts

Assistance listings
Funding instrument
Grant
Category
  • Health
Eligible applicants
  • For Profit Organizations
  • State Governments
  • Higher Education Inst. (Private)
  • Public or Indian Housing Auth.
  • Small Businesses
  • City/Township Governments
  • Non-501(c)(3) Nonprofits
  • Other
  • Higher Education Inst. (Public)
  • Tribal Governments (Federally Recognized)
  • Independent School Districts
  • Tribal Organizations (Not Federally Recognized)
  • County Governments
  • Special District Governments
  • 501(c)(3) Nonprofits
Points of contact

Opportunity details come from Grants.gov. Updated .

About this opportunity

Written by GovTribe AI ·

The National Institute of General Medical Sciences (NIGMS) is soliciting applications for the Maximizing Investigators' Research Award (MIRA) (R35 – Clinical Trial Optional) with an application due date of May 26, 2028. This is a forecast for continued program support. MIRA provides single-award support for an investigator's entire research program within NIGMS's scientific mission, consolidating multiple grants into one funding instrument to increase investigator stability and flexibility.

NIGMS invites applications from eligible NIGMS-funded investigators and from NIH-defined New Investigators whose research aligns with NIGMS's mission. Current Early-Stage Investigators (ESIs) must apply through a separate ESI MIRA NOFO. Renewal applications from all current MIRA grantees, including those previously funded as ESIs, are permitted. Eligible applicant types include higher education institutions (public and private), nonprofits (501(c)(3) and non-501(c)(3)), for-profit organizations, state and local governments, tribal governments and organizations, and independent school districts.

Non-domestic entities and non-domestic components of U.S. organizations are not eligible. Foreign subawards and subcontracts are prohibited; applicants may conduct unfunded international collaborations, engage foreign consultants, or procure equipment and supplies from foreign vendors.

Awards provide up to $750,000 in direct costs annually for a maximum project period of five years. Award amounts typically range from $275,000 to $750,000 in annual direct costs depending on investigator funding history. Clinical trials are optional; mechanistic trials are permitted, but trials testing intervention safety and efficacy are not allowed. Applications undergo scientific peer review with funding decisions based on scientific merit, available funds, relevance to NIGMS mission priorities, and portfolio breadth. NIGMS prioritizes the MIRA program over R01 awards and generally limits investigators to one NIGMS R01 (including multi-PI R01s).

This opportunity is assigned to the Biomedical Research and Research Training program (CFDA 93.859).

Synopsis

The Maximizing Investigators' Research Award (MIRA) provides support for individual investigators for research within the scientific mission of NIGMS via a single grant to achieve the following:Increase the stability of funding for NIGMS-supported investigators, which could enhance their ability to take on ambitious scientific projects and approach problems more creatively;Increase flexibility for investigators to follow important new research directions within the NIGMS mission as opportunities arise, rather than being bound to specific aims proposed in advance of the studies;More widely distribute funding among the nation's highly talented and promising investigators to increase overall scientific productivity and the chances for important breakthroughs;Reduce the time spent by researchers writing and reviewing grant applications, allowing them to spend more time conducting research;Reduce the administrative burden associated with a PD/PI managing multiple NIGMS research grants; andEnable PD(s)/PI(s) to devote more time and energy to mentoring junior scientists in a more stable research environment.This NOFO invites applications from eligible NIGMS-funded investigators and from New Investigators proposing research that is aligned with NIGMS' scientific mission. The NOFO also allows renewal applications from all current MIRA grantees (including those previously funded as Early-Stage Investigators). Current Early-Stage Investigators (ESIs) should apply through the ESI MIRA NOFO, not this NOFO.

Eligibility

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/Foreign CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. This new requirement was effective, May 1, 2025.Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.

Files

File Type Posted
PAR-26-121-Revised-Full-Announcement.html HTML file
PKG00291740.pdf PDF
PAR-26-121-Full-Announcement.html HTML file

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar grant opportunities
  • Ask GovTribe AI about this opportunity
Try for free Login